

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 586 333 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
19.10.2005 Bulletin 2005/42

(51) Int Cl.7: **A61K 45/06, A61P 35/00**

(21) Application number: **05090011.7**

(22) Date of filing: **20.06.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
LT LV RO SI

(72) Inventors:
• Siemeister, Gerhard
13503 Berlin (DE)
• Haberey, Martin
12169 Berlin (DE)
• Thierauch, Karl-Heinz
14159 Berlin (DE)

(30) Priority: **23.06.2000 EP 00250194**
28.06.2000 EP 00250214

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
01965012.6 / 1 292 335

Remarks:

This application was filed on 27 - 01 - 2005 as a
divisional application to the application mentioned
under INID code 62.

(71) Applicant: **Schering Aktiengesellschaft**
13353 Berlin (DE)

(54) **Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)**

(57) The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF

receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.




Fig. 1

Description

[0001] The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

[0002] Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

[0003] The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442, 1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al., Nature 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

[0004] The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., Cell 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

[0005] The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al., Lab.

[0006] Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al., Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

[0007] In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Gold-

man et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

[0008] The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kai-painen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

[0009] Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

[0010] However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

[0011] Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

[0012] Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the

VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


[0013] A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al., Proc. Am. Associ. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Associ. Cancer Res., San Francisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as Pseudomonas exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhMAbVEGF) and by Presta et al. (1997), Cancer Res. 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), Nature 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described.

[0014] Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

[0015] Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A.94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

[0016] Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I




20 in which

r has the meaning of 0 to 2,

n has the meaning of 0 to 2;

R_3 und R_4 a) each independently from each other have the meaning of lower alkyl,


b) together form a bridge of general partial formula II,



40 wherein the binding is via the two terminal C- atoms, and

m has the meaning of 0 to 4; or

c) together form a bridge of partial formula III




55 wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G has the meaning of C₁-C₆-alkyl, C₂-C₆-alkylene or C₂-C₆-alkenylene; or C₂-C₆-alkylene or C₃-C₆-alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-NH-CH₂-, oxa (-O-), thia (-S-) or imino (-NH-),
 A, B, D, E and T independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,
 Q has the meaning of lower alkyl, lower alkyloxy or halogene,
 R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
 X has the meaning of imino, oxa or thia;
 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygen atom, or a salt thereof.

[0017] A preferred salt is the salt of an organic acid, especially a succinate.

[0018] These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

[0019] Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example anthranil acid derivatives of general formula IV




in which


A has the meaning of group =NR²,

W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,

Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-(CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the group



or A, Z and R¹ together form the group



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

X

Y

p

R¹

R²

R³

R⁴, R⁵, R⁶ and R⁷

has the meaning of 0 - 3,

has the meaning of 1 - 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,

has the meaning of group -(CH₂)_p,


has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group




R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.



[0020] These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

[0021] More preferentially compounds of genearel formula V




in which


R¹ has the meaning of group



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R^8 is $-CH_3$, fluoro, chloro or $-CF_3$

in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N=C$, $-CH_3$, $-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

R^2 has the meaning of pyridyl or the group



and

R^3 has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

[0022] These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

[0023] A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

[0024] Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of

the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

[0025] For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately.

[0026] The inventive compositions comprise as compound I or as compound II at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

[0027] Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

[0028] Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

[0029] The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

[0030] The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

[0031] Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also

possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

[0032] For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

[0033] These formulations and application forms are also part of the instant invention.

[0034] Combined functional interference with VEGFNEGF receptor systems and with Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGFNEGF receptor systems or with Angiopoietin/Tie receptor systems and targeting of cytotoxic agents via VEGFNEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

[0035] The invention is also directed to a substance which functional interferes with both VEGFNEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGFNEGF receptor systems and Angiopoietin/Tie receptor systems.

[0036] VEGFNEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor tyrosine kinases Tie1 and Tie2.

[0037] Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of the present invention can be applied orally, parenterally, or via gene therapeutic methods.

[0038] Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

[0039] The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

Example 1

[0040] Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

[0041] Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nude* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase

inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0042] Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days. This result clearly demonstrates the superior effect of a combination of interference with the VEGF-ANEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

[0043] Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

[0044] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0045] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

[0046] The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

[0047] Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

[0048] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0049] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-ANEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

[0050] Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

[0051] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals re-

ceiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-ANEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

[0052] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

[0053] The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the VEGF/NEGF receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

[0054] Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

[0055] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0056] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

[0057] Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

[0058] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

[0059] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure

6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

[0060] The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

Description of the figures

[0061]

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

mock, con. = treatment group 1
 mock+VEGF-A = treatment group 2
 sTIE2-c113 = treatment group 3
 sTIE2-c113+VEGF-A = treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

Sequence Identifier

5 <110> Schering Aktiengesellschaft

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

10 <130> 51867AEPM1XX00-P

<140>
<141>

15 <160> 59

<210> 1
<211> 1835
<212> DNA
<213> Human

20 <400> 1

ttttacagtt ttccttttct tcagagtta ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
25 tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaaca gccaaaaaac cataatggtg ccacagggat ggagcagga agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaaccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
30 aagaaaaacca acaacaacaa aaagcgagg actgtctgtt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcgga cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccaaacgca acctaacca agcaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc ttgagagaa cgcatacctt 840
35 gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtcca tctgttccca gaatccgagg gagaactgag 960
gtgatcgta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatag 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggagaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacag 1140
40 gcaaacagga atgcagtaaa cgtccacgtc cgtccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgc ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcagtggggt ctgcgatagc tcatttaatg ttaaagcca tcaggggcct ctctcccggt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcgg tctggctcgtc tctcctgca 1440
ggctgggcag ctggccacca cttctccgac tgcaccctc caacaagcat cgcaggcac 1500
45 tgtcctcggg ggtacagacc gtggtccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgtag gccgtgctgt ctggggctcg aggtctttc tgctggtgct 1620
cttggacggg cgggtagttc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
atthtgggtc attcatatct acgcagagt ccaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggaact gccatccaag 1800
50 gagacgaacc acgcccgggg gtgcggaagc ggct

<210> 2
<211> 581
<212> DNA
55 <213> Human

EP 1 586 333 A2

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagacc ctggggcctg tgctaccag 60
acactaaca cagtccttat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180
agtgcacaca cctggaaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
tgggccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
10 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa ttagggccct 540
cacctcccca tgacatcctc catgagcctc ctgatgtagt g

<210> 3

<211> 516

15 <212> DNA

<213> Human

<400> 3

20 tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
tcctgcgat tgcaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcatcaaca 420
25 tccaagatgc ttttccagtc aaaagaacca gcaaatactt ttctctggat ctcaactcatg 480
atgaagttcc agagtttgtt gtgtaaaagtc cgtctg

<210> 4

<211> 1099

30 <212> DNA

<213> Human

<400> 4

35 cccacaacac agggggcctg aaacacgcca gcctctctc tgtggtcagc ttggccagct 60
cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
gggggtgcgtc ttggccttgc cgtgccctca tcccccggtc gaggcagcga cacagcaggt 240
gcaccaactc cagcaggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300
tgaagatggt ctctccgtg gggcgagaga caaagcagtc cacgaggtag gggcagggtg 360
ctcgttgcca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
ggaagcctgc ctctagcaca ctcttgaga gcacactggc gacatagggt cccatcagtg 480
40 ctccgcggat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgctcta 540
cgcccgccag cgcccgctcc acctgtgggt ccttggccgg cagtgccgcg agctccccct 600
ccttctgccc cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660
gggtgggtgt gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720
aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
45 agagcaccgt cagccagatc ttaccacca cggctcagtg ctctggacc tgggtccagca 900
acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
gcacgtcagt gtgtcagcat ggcattcttc tcgttcgccc agcaacaagc ctgcaggag 1020
gtctgccacg cccgttctac cgcctgctg ccgggcggcc caggtggagg tggggacgat 1080
ggccggagtg acgcccgcg

50 <210> 5

<211> 1015

<212> DNA

<213> Human

<400> 5

55 gaggataggg agcctggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

EP 1 586 333 A2

5 aaaaagtgct ttttgaaaa gttgaggttg aaatgatggg aaccaacatt ctttggaattt 120
 agtggggagc ataatagcaa acacccccctt gggttcgcaca tgtacaggaa tgggacccag 180
 ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaagtg gggccagggc 240
 ccagacccaa gaggagaggg tgggtccgcag acaccccggtg atgtcagcat cccccgacct 300
 gccttctggc ggcacacctcc ggggtgctgtg ttgagtcagc aggcattggg tgagagcctg 360
 gtatatgtctg ggaacagggt gcagggggcca agcgttccctc cttcagcctt gacttggggc 420
 atgcaccccc tctcccccaa acacaaacaa gcacttctcc agtatgtgtc caggacagg 480
 gtcccttcag tcctctgtgtt atgacctcaa gtccactctg ggccctgcag cccagcctgt 540
 gttgtaacct ctgctctctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
 10 aatgtgtctc cctccctggg gtctccacag cttccacgag aatgccacag gggccgtgca 720
 ctgggcaggc ttctctgtag aacccacagg gcttcggccc agaccacagc gtcttgccct 780
 gagcctagag cagggagtc cgaacttctg cattcacaga ccacctccac aattgttata 840
 accaaaggcc tcctgttctg ttatttctact taaatcaaca tgctattttg ttttctactca 900
 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgttca cgtgctagt 960
 acgtttttct tcttacacat gaaaaataat gcataagtgt tagaagaaaa aaaaa
 15 <210> 6
 <211> 2313
 <212> DNA
 <213> Human
 20 <400> 6
 ccagagcagg cctggtggtg agcagggagc gtgcaccgga cggcgggatc gagcaaatgg 60
 gtctggccat ggagcacgga ggggtcctacg ctcgggcggg gggcagctct cggggctgct 120
 ggtattacct gcgctacttc ttctctctcg tctccctcat ccaattcctc atcatcctg 180
 ggctcgtgct cttcatggtc tatggcaacg tgacagtgag cacagagtcc aacctgcagg 240
 25 ccaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300
 ccaacttgac caaggagctc aacttcacca cccgcgccaa ggatgccatc atgcagatgt 360
 ggtctgaatgc tcgccgcgac ctggaccgca tcaatgccag cttccgccag tgccagggtg 420
 accgggtcat ctacacgaac aatcagagg acatggctgc catcatcttg agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcattgctga 540
 atcagaagg gaagacgctg gaggtggaga tagccaagga gaagaccatt tgactaagg 600
 30 ataaggaaag cgtgctgctg aacaaacgcg tggcggagga acagctggtt gaatgcgtga 660
 aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaagggtga 720
 agcctctgct ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840
 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
 ggtggaggag tccagccgga gcttccgggc ggatatcgaa cgctgggcc gcgagaactc 960
 35 agacctccaa cgccagaagc tggaaagccca gcagggcctg cgggcccagtc aggaggcgaa 1020
 acagaagggt gagaaggagg ctacggcccg ggaggccaag ctccaagctg aatgctcccg 1080
 gcagaccag ctacgcgtgg aggagaaggc ggtgctgcgg aaggaaacag acaacctggc 1140
 caaggagctg gaagagaaga agaggaggc ggagcagctc aggatggagc tggccatcag 1200
 aaactcagcc ctggacacct gcatcaagac caagtgcag ccgatgatgc cagtgtcaag 1260
 gccccatggg cctgtcccca acccccagcc catcgacca gctagcctgg aggagttcaa 1320
 40 gaggaagatc ctggagtccc agaggcccc tgcaggcatc cctgtagccc catccagtgg 1380
 ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctcgccggtt tgcggaggat 1440
 gcagggatat gctcacagcg cccgacacaa ccccctcccg ccgcccccaa ccaccagggg 1500
 ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcaccccg 1560
 cctcacgac cctcaccag agcacacggc cgcgagatg acgtcacgca agcaacggcg 1620
 ctgacgtcac atatcacctg ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680
 45 tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740
 acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800
 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagtg 1860
 acaacacaca ccatgacaac gacacctata gatattggc caacatcaca tgcacgcatg 1920
 cctttcaca cacactttct acccaattct cacctagtgt cacgttcccc cgaccctggc 1980
 acacgggcca aggtacccac aggatcccat cccctcccgc acagccctgg gccccagcac 2040
 50 ctcccctcct ccagcttccct ggcctcccag ccacttcctc acccccagtg cctggaccgg 2100
 gaggtgagaa caggaagcca ttacactccg ctccctgagc gtgagtgttt ccaggacccc 2160
 ctcgggggcc tgagccgggg gtgagggtca cctgttgtcg ggaggggagc cactccttct 2220
 ccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280
 agtaaatcct taaaaaaaaa aaaaaaaaa aaa
 55 <210> 7
 <211> 389

EP 1 586 333 A2

<212> DNA
<213> Human

<400> 7

5
gccccaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
10 gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8
<211> 157
<212> DNA
15 <213> Human

<400> 8

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
20 gaagcaggaa gcaagccac tcaaacgtga aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

<210> 9
<211> 561
<212> DNA
25 <213> Human

<400> 9

aatagtcaaa acataaaca aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
30 tgaactgaac tattctgtta catatgggtg acaaatctgt gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaa atataccatca ttgtgattaa 420
ttaaaccctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgac 480
35 ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctaggaaa a

<210> 10
<211> 1508
<212> DNA
40 <213> Human

<400> 10

cacaaacacg agagactcca cggctctgcct gagcacccgc agcctcctag gctccagcac 60
tcgcaggtec attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
45 gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatect tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaatct 240
gagctcaagc caggtgagct taagccactg agcaaggaa atttgggcct gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctacccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
50 tgtgctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
gggtgcatgt ccctcttttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaaagt tcccactgtc ccccttagga actttgaaaa accaacaatg 720
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactttgg cactgttaat agaaagtgtg gatagtcctt 840
60 gctgttttgc gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
ctcagctaatt ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960
55 ctaaggaac acagacactc ctaggcaaaag tttttgtttg tgaatagtac ttgcaaaact 1020

EP 1 586 333 A2

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
 gtatatataa taatatTTTg aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaaata tatactaata tgttgtagat tcggaagaat gtgaatcaat cagtatgttt 1200
 ttagattgtg ttttgcctta cagaaagcct ttattgttaag actctgattt ccctttggac 1260
 ttcattgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgttttagt gtaaagaata tttattttgaa gttttattat tttataaaaa agaattattta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaa 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa
 10 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11
 20 gggcagggtg tcagggcaca catttcccggt ccattgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cgggtgagaca agtgccccgac 120
 aggatgggtg gccacagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180
 ctgtcctgct ggaaccccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagtttttg 360
 acctcggccg cgaccacgct gggataccga
 25 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12
 35 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggctgagg atcacttgag 120
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcacaaa tacaattgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cgggtttaca gtgatatcat tataattcat ttggcagaat 360
 cattacatca ttgggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 taggataaca ggtctgcctg tttgaagatg aaaaataata cccattttaa atttgcccta 480
 ctcaatttcc ttctcagtc ctttttaact tttaaacagc taatcactcc catctacaga 540
 ttaagtggtg tatgccacca aaaccttttg ccaccttaa aatttccttc aaagttttaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 cacacagtgt agtcaagccg actctccata cccaagcaag tcactccatg ataaaaacgt 720
 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcaccagca ccatacctca caggagtcga ctcccacgag ccgctgtgat 960
 ataagagttc ttttgatgac g
 45 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 50 <400> 13
 55 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
 tctctcccc agagcgacc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggtcatca cgattcagag aaatcaagat ctatgaccat ttaggcaaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360
 acttcagcat atttagttgt cattaaaatt aagctgatat t
 60 <210> 14

EP 1 586 333 A2

<211> 1002
<212> DNA
<213> Human

5 <400> 14

```

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
tttgaaaatg ttaaatataa gtccatttct ctttgtccag ctgggttttag ctagaggtag 180
ccaattactt ctcttaaggt ccatggcatt cggcaggatt ctataaaagc caagttaact 240
10 gaagtaataa tctggggccc atcgccacccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcat ttttcactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
tggtctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaaa aatgggtgcc attgctccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat cattttattat gtaggagcct tgatatctct gcaaaataga 600
15 attaatagag ctcaaaggga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720
attcaataaa cattagccaa gctaattgtc caagccactg tgccaggat taacaatata 780
acaacaataa aagacacagt ccttcctctc aagggtgttca gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
gcctatgttc tcagatatc ttggttaggtc aggagtggga acccaaatc aattctttta 960
20 acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

```

<210> 15
<211> 280
<212> DNA
<213> Human

25 <400> 15

```

cgaggtgggc caccogtgtc tggctctgaga tttttaaatg aggattacat taccctattt 60
ataatattcc tattctaadc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
30 aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
aactgtatta tgactctcaa tatttaaaaca tttaaaaaaa tgttagtggt tgtaaagcac 240
caatcttaac tatttcacct gcccgggcgg ccgctcgagg

```

<210> 16
<211> 2041
<212> DNA
<213> Human

35 <400> 16

```

ccccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagagggtta gcatttttta ggtaaaaaata tgggtgcccc tacagggatc atgcaacttc 120
40 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataactctcta gttgattttc aaggacttga 300
atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
45 aaaactgaag atagaccatt taaatgcttc taccaaatth aacgcagctt aattaggac 480
caggtagcata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaattttaag aggttagatt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
ataaaaacaa gcaactgagt tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
tagatatttg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720
gcattttgga ctctctcagg atcaaaatac gagtctgcca actgtattaa atcctcctcc 780
50 accccctcca ccagttgggc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggccggg gctcgagcat tcaactcttg 900
ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaacacctg tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaaaaaaaa acccattctt 1140
55 ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctgggtggtac atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

```

EP 1 586 333 A2

5 taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380
 catcagtgccc tgaaggcttt aatttttttag caaggttctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500
 ccaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560
 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620
 gttttctcag cattttgcag agaggcacag ttttcacaat aatattggtt atcaccagta 1680
 agaattctctg gagcccaaaa aataatttag taagtcagtt actgaagggtg tggtttcacc 1740
 tcccggtttc tgaggtacat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800
 agtgttttca gaacagtaaa actcattagg aggactgcct atgggttttt cattcacaag 1860
 10 tgagtcacag atgaaggcag ctgttggttg attataaact actggctctt ctgaaggacc 1920
 gggtagacag gcttgcatga gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaagatg ctgtaaaggc 2040
 t
 <210> 17
 <211> 235
 15 <212> DNA
 <213> Human
 <400> 17
 20 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagacccttc 60
 acctctacaa ataaaaaatt aaaaaattag ccaggtgtgg cagcgaacaa ctgtagtctc 120
 agatactcag gagactgagc cacttgagcc caagaagttc aaggttacag 180
 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta
 <210> 18
 <211> 2732
 25 <212> DNA
 <213> Human
 <400> 18
 30 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120
 aaatattatc ttcttgggtga tcacattgtg caaaatgggt aagcattcaa acactttgaa 180
 accagattct agcagggttg aaaacattaa gtcttgggtg cttggcgctt tcgctcttct 240
 gtgtcttctt ggcctcacct ggtcctttgg gttgcttttt attaatgagg agactattgt 300
 gatggcataa ctcttcacta tatttaatgc tttccaggga gtgttcattt tcacttttca 360
 ctgtgctctc caaaagaaaag tacgaaaaga atatggcaag tgcttcagac actcactactg 420
 35 ctgtggaggc ctcccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480
 cagtgctcgc tattcctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540
 gagaaaaaaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600
 tcaagggtgc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660
 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagtg 720
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaaggggtg 780
 40 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840
 agaaaatgat catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900
 acctcgagct cacgctacca gtcaaacctg tgattggag tagcagcagtg gaagatgatg 960
 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggtctg gagctccatc 1020
 acaaagaact cgaggcacca cttattcctc agcggactca ctcccttctg taccaacccc 1080
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 45 aagatcacct acagtcccc aacagagact ctctttatag aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agcctgaca tggagaaga cctctctccc tccaggagga 1260
 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc aggggcaata gtgatggtta tataatcccc attaacaaag 1380
 aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctgggtt acaagtcttt 1440
 50 aatcatcacag ctaaggaatt ccaagggcca catgagagta ttaataaata aagacaccat 1500
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560
 tgggtgtaaaa aagatgactg aaccttgagc ttctgtgaat ttttataaaa catacaaaaa 1620
 ctttgtatat acacagagta tactaaagtg aattatttgt tacaagaaaa agagatgcca 1680
 gccagggtatt ttaagattct gctgctgttt agagaaattg tgaacaacgc aaaacaaaac 1740
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800
 55 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860
 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatacag 1920
 tttgcagttc actgcaaatc ttttacatta aggcaaaagt tgaaaacatg cttaaccact 1980

EP 1 586 333 A2

5 agcaatcaag ccacaggcct tatttcatat gtttctctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatatatttg ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaact gaaatataat tgtcattaaa ataatttttaa agagtgaaga aaatattgtg 2160
 aaaagctctt ggttgacacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220
 ctactcattt tcaacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280
 tattactttac atttaaattt cttatttgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tctttgaagc cagttatgtc atgccttgca caaaagtgtat gaaatctaga aaagattgtg 2400
 tgtcacccct gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460
 tttctagtga acaaaagggt cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520
 10 actcttccat attccttctg cctatattta gtaatttaatt tattttatga taaagtctta 2580
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640
 ttaataatga gcccatcact aatatccagt gtaaagtta acacggttg acagtaata 2700
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

 <210> 19
 <211> 276
 15 <212> DNA
 <213> Human

 <400> 19

 20 ctccctaaat gatttttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120
 tattccctat atagcaaaac aaaaccaggga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gccgcgacca cgctgg

 <210> 20
 25 <211> 2361
 <212> DNA
 <213> Human

 <400> 20

 30 attgtaccag ccttgatgaa cgtgggcccct gcttcgcttt tgagggccat aagctcattg 60
 cccactgggt tagaggctac cttatcattg tctcccgtga ccggaagggt tctcccaagt 120
 cagagttttac cagcagggtat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttgctg 240
 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300
 35 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360
 ttgcccaagag ccagcatctg gacagtgatg ggctggccca gattttcatg cagtatggag 420
 accatctcta cagcaagggt aaccacgatg gggctgtcca gcaatataat cgaaccattg 480
 gaaagtgtga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600
 tgctcctcaa cgtctatacc aagctcaagg acagctcgaa gctggaggag ttcatacaaga 660
 40 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggt ctcgggcagg 720
 ctggctacta ctcccagtc ctgtatctgg cggagaacca tgcacatcat gagtgggtacc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggaagc 840
 tgctcttttg gcaggcagag agcaacatga agcgtacgg caagatcctc atgcaccaca 900
 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg ccagcctcg 960
 aaggccgcag cgatagggtg gccccaggct gcagggccaa ctctgaggag ttcatcccca 1020
 45 tctttgccaa taaccgcgga gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggccc 1140
 acgagaagga tccacagggt aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200
 gtggctcgct ctgacgagtc tttgacaagg ccctggctct gtgccagatg cagcacttcc 1260
 aggatgggtg cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320
 acatgcagca cgagcagtac cggcagggtc tcagcgtgtg tgagcgccat ggggagcagg 1380
 50 accctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctcttctag 1500
 tgggtgcagac cctggcccaa aactccacag ccacactctc cgtcatcagg gactaccttg 1560
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcgg 1620
 accgagagga gaccacccgt atccgcccagg agatccaaga gctcaaggcc agtccctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740
 55 tctgtgtgg ccactcctt caccaacact gctttgagag ttactcgga agtgatgctg 1800
 actgccccac tgcctcctt gaaaaccgga aggtcatgga tatgatccgg gccaggaac 1860
 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

EP 1 586 333 A2

ctgtgattgc tgactacttt ggcagagggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgcccagg 2160
 5 gctccactct catctaattgt cacagccctc acaagactaa agcgggaactt tttcttttcc 2220
 ctggccttcc ttaatttttaa gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaac tctgaagtt 2340
 ttgaaaaaaa aagctggttt c

 <210> 21
 10 <211> 179
 <212> DNA
 <213> Human

 <400> 21

 15 aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaagggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

 <210> 22
 <211> 905
 20 <212> DNA
 <213> Human

 <400> 22

 25 tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaacg gaatgccaag gtccaagcca ggctcaagaa 120
 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttccctaagg 180
 caaagggtact tttgatacag agtctgatct ttgaaactgg tgaactcctc ttccaccat 240
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300
 tagggtcatt aataactatg aatatactct ttagaagggt accattttgc actttaaaagg 360
 gaatcaattt tgaatatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 30 gggagctgga agagccttgg aagtttctat tacaaataga gcaccatata cttcatgcca 480
 aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaata aactcgcaag 540
 gtctgaccag ttcttggtaa caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660
 ggcagggtct cctaattgtc attattacat ttccattccg aatgccagat gttaaaagt 720
 cctgaagatg gtaaccagc tagtgaggaa taaatacccc accttgcca gtccacagag 780
 35 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840
 ccatggattg cagtctcttc ctccagacca gctgcttatt tcctcagggg cccagggaat 900
 gttga

 <210> 23
 <211> 2134
 40 <212> DNA
 <213> Human

 <400> 23

 45 ggtctcttct ttcttttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60
 gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa aagttttttt 120
 cattagaagt aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300
 accaggatac gactgttgga ccagctgctg gagatggacc tgctaccctc cagcagctc 360
 50 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420
 tcatttttgt tccggcggtt catctctcct gtgtgattgt actgattttc atgagacaca 480
 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaggt 540
 tggagggtact aagctcattg tgtctcctct agcttttacc agcatctaatt gcttcactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagtgtt ttttctctca 660
 aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaagagga agccatttgc 720
 gttatttcac gttgctgagc ctttctctca tgttgaacaa tctgaagttt taattctcgg 780
 55 tagaataaat gtataaacat tctctgaaac catagcagcc ataaacagt ctgggtcaag 840
 atcctatttg tactccttct tccccccatt gttagttagg taaagtaaaa cagggtcttag 900

EP 1 586 333 A2

5 taaaatctca cttttctcct acttttccatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatatgt ctaacttttt ttgacaattg ctttgttttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080
 tgctatatca ctgctcagag gttataatac tctactaact atcctatcaa atttgcaact 1140
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc cactttactg 1200
 atacacctca ctgggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttccctcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380
 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 10 ggtctgcaca aggtctgggt ctggctgggt tcaacttctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgccacag 1740
 taagaaacctg gatggtcaag ggctcttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacttttgta cataatgtct tgctctaagg 1860
 15 tggacaaagt gtagtacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gttcctggat cccctctggt tccgctgttt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040
 tttttttaca agtagatcca tttccccgcg aaacaccaca tttatcaaac ttctttttgg 2100
 agtctatgat gcgatcacia ccagctttta caca
 20 <210> 24
 <211> 1626
 <212> DNA
 <213> Human
 <400> 24
 25 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaaactttg caaatatgag catcatatgt gtttaaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacagggt gaacaaacgt 240
 30 agttgttttt tactgatact aaatgtttggc tacctgtgat tttatagtat gcacatgtca 300
 gaaaaaggca agacaaatgg cctctgtgac tgaatacttc ggcaaaactta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata ttgttagagc ttgcgtagaa tggattacat 420
 ggtagtgtat cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgtaagcata tctgaattta cttataaaag atggtttttag 540
 aaagctttgt ctaaaaaattt ggcttaggaa tggtaacttc attttcagtt gccaaagggt 600
 35 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaac tcagggtacc cttgaaggat atgctggcag 780
 ccactctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840
 tctgggaatg attagttagt cctgttacca tcccagaat ttcaggggca tctgtgggtt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 40 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtag tgcaatcaca 1320
 45 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcactctat ggaactctt gatgcagtgt cttttgtatg gaataaattt 1440
 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 attataacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatatatt 1560
 tacttgaaaa tatttttaaat ggaattttta ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa
 50 <210> 25
 <211> 1420
 <212> DNA
 <213> Human
 <400> 25
 55 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

EP 1 586 333 A2

5
10
15
20

ttcattgaaa	tccttgctac	ttctcttcct	cctcaatgaa	agacacgaga	gacaagagcg	120
acacaagctt	aagaaaaacg	agcaagggaag	agtatcttca	ttattctcat	tttctctgag	180
ttggaaacaa	aaacatgaag	gactccaact	agaagacaga	tatttacatt	taaatagatt	240
agtgggaaaa	ctttaagagt	ttccacatat	tagttttcat	tttttgagtc	aagagactgc	300
tccttgctact	gggagacact	agtagtatat	gtttgtaatg	ttactttaaa	attatctttt	360
tattttataa	ggcccataaa	tactggttaa	actctgttaa	aagtgggcct	tctatcttgg	420
atggtttcac	tgccatcagc	catgctgata	tattagaaat	ggcatcccta	tctacttact	480
ttaatgctta	aaattataca	taaaatgctt	tatttagaaa	acctacatga	tacagtgggtg	540
tcagccttgc	catgtatcag	tttcacttga	aatttgagac	caattaaatt	tcaactgttt	600
aggggtggaga	aagaggtact	ggaaaacatg	cagatgagga	tatcttttat	gtgcaacagt	660
atcctttgca	tgggaggaga	gttactcttg	aaaggcaggc	agcttaagtg	gacaatgttt	720
tgtatatagt	tgagaatttt	acgacacttt	taaaaattgt	gtaattgtta	aatgtccagt	780
tttgctctgt	tttgccctgaa	gttttagtat	ttgttttcta	gggtggacctc	tgaaaaccaa	840
accagtacct	ggggagggtta	gatgtgtgtt	tcaggcttgg	agtgtatgag	tggttttgct	900
tgtattttcc	tccagagatt	ttgaacttta	ataattgcgt	gtgtgttttt	ttttttttaa	960
gtggctttgt	ttttttttct	caagtaaaat	tgtgaacata	tttcctttat	aggggcaggg	1020
catgagttag	ggagactgaa	gagtattgta	gactgtacat	gtgccttctt	aatgtgtttc	1080
togacacatt	ttttttcagt	aacttgaaaa	ttcaaaaggg	acatttggtt	aggttactgt	1140
acatcaatct	atgcataaat	ggcagcttgt	tttcttgagc	cactgtctaa	attttgtttt	1200
tatataaagt	ttttatactg	attggttcat	agatggtcag	ttttgtacac	agactgaaca	1260
atacagcact	ttgccaaaaa	tgagtgtagc	attgtttaaa	cattgtgtgt	taacacctgt	1320
tctttgtaat	tgggttgtgg	tgcattttgc	actacctgga	gttacagttt	tcaatctgtc	1380
agtaaataaa	gtgtccttta	acttcaaaaa	aaaaaaaaaa			

<210> 26
<211> 689
<212> DNA
<213> Human

<400> 26

30
35

aaacaaacaa	aaaaaaaaagt	agtactgtat	atgtaaatac	tagcttttca	atgtgctata	60
caaacaatta	tagcacatcc	ttcctttttac	tctgtctcac	ctccttttagg	tgagtacttc	120
cttaaaataag	tgctaaacat	acataacacg	aacttgaaag	ctttgggttag	ccttgcccta	180
ggtaatcagc	ctagttttaca	ctgtttccag	ggagtagttg	aattactata	aaccattagc	240
cacttgtctc	tgcaccattt	atcacaccag	gacagggctc	ctcaacctgg	gcgctactgt	300
catttggggc	cagggtgattc	ttccttgcaa	gggtgtctct	gtacctgccc	ggcgggccgc	360
tcgaagcgtg	gtcgcggccg	aggtactgaa	aggaccaagg	agctctggct	gccctcagga	420
attccaaatg	accgaaggaa	caaagcttca	gggtctctgg	tggtgtctcc	cactattcag	480
gaggtggctg	gaggtaacgc	agcttcattt	cgtccagtc	tttccagtat	ttaaagttgt	540
tgtcaagatg	ctgcattaaa	tcaggcaggt	ctacaaaagg	atcccaagca	tcaaacatgt	600
ctgtgatgaa	gtaatcaatg	aaacaccgga	acctccgacc	acctcctgaa	tagtgggaga	660
cacaccacaga	gcctgaagtt	tgctcttcg				

<210> 27
<211> 471
<212> DNA
<213> Human

<400> 27

45
50

tcccagcggc	atgaagtttg	agattggcca	ggccctgtac	ctgggcttca	tctccttcgt	60
ccctctcgct	cattgggtggc	accctgcttt	gcctgtcctg	ccaggacgag	gcaccctaca	120
agccctaacc	caggccccgc	ccagggccac	cacgaccact	gcaaacaccg	cacctgccta	180
ccagccacca	gctgcctaca	aagacaatcg	ggccccctca	gtgacctcgg	ccaccacagc	240
gggtacaggc	tgaacgacta	cgtgtgagtc	cccacagcct	gcttctcccc	tggtgtgctg	300
tgggtctggt	cccggcggga	ctgtcaatgg	aggcaggggt	tccagcacaa	agtttacttc	360
tgggcaattt	ttgtatccaa	ggaaataatg	tgaatgcgag	gaaatgtctt	tagagcacag	420
ggacagaggg	ggaaataaga	ggaggagaaa	gctctctata	ccaaagactg	a	

<210> 28
<211> 929
<212> DNA
<213> Human

<400> 28

EP 1 586 333 A2

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctgggtgg ctttccctc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccgga 180
 gattccaccc cagccctggt acaagtctac tgtcatccac atgactgttg gaggttccct 240
 gcctttcagt gccatctctg ttgagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctgggtgtg 420
 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac ttctctact cagttttcta 480
 10 ttatgcccgg cgctccaaca tgtctggggc agtacagaca gtagagtctt tcggctactc 540
 cttactcact gggttatgtct tcttctcat gctgggcacc atctcctttt tttcttccct 600
 aaagtccatc cggatatctt atgttaacct caagatggac tgagtctgt atggcagaac 660
 tattgtgttt ctctcccttt ctctatgccc tgttgaactc tcctaccagc ttctctctg 720
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780
 ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840
 15 taagttgcct ttagttttgg tctgtatttt tctttttaca attacaaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa
 <210> 29
 <211> 1775
 <212> DNA
 <213> Human
 20
 <400> 29
 25 gaacgtgatg ggaacttttg gaggatgtct gagaaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgcaact tggctggcgg cagcccgggc ggcttccagt ccgtgtgggg 180
 cgccccgctg gccttctcct cgtaggactc cccaaactcg ttactctgct gtttatccac 240
 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccgggtga gacgtgggca tgggtgatgat gaaggcaaa acgtcatcaa tgaagggtgt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgtagtt 420
 cacaagagc tggggcagca tgaagaggaa accaaaggca tagaccccg tgaagagct 480
 30 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 cccgacacag agaggggtaca gcaggatga caagtacttc atggcctgag tatcgtactc 600
 ctcggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcacttcca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 cacggtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgctcttctt 840
 35 cttcttccag aaactgatgt catttttaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccagggaagta taagttggta tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gcccagtgga gaccttgtcg taggacacgg tgaggggcag 1080
 ctcggtgggt gagcggttta tgaccatcag gtccttcacg cggttgctga gctggtcgat 1140
 gaacaggatg ggcaggtaat gcacggtttt cccagctgg atcatcttca tgtaccgatg 1200
 40 cacatcggca ggcaggagg acccgtaaaa gacaaagttg tccgccatca cgttcagcgc 1260
 cagcccggt cgccagtggg aactggctc atccagggca ctgctcggt tcttctccgc 1320
 ctcgatctgc tgtgtatcag actcccggg gagcagggtt atttctctg gcttggggac 1380
 catgtagggt gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440
 cccagcgtga tggagggaaga ttaggcata cagcgtccca ttgtttctcg ttttctttg 1500
 tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 45 gaccaggtcg atgtgttct cagcaccag gtgggacctc gtcgtggtgt acacgctcag 1620
 ctgcagcttg ggccgcccgg ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 gcgggtgtag acgatgccgt acatgacca gcagggtgtc accacgtaga ccacgaacac 1740
 gccaccacc aagctggtga aggagctgct gcccc
 <210> 30
 <211> 1546
 <212> DNA
 <213> Human
 50
 <400> 30
 55 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120

EP 1 586 333 A2

5 acaccatcta cgggcaccat ggaactgctt caagtgacca ttctttttct tctgcccagt 180
 atttcgagca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttgttact 240
 acaacaaaac catctataac aacacaaaac acagaatcat tacagaaaaa tgttgtcaca 300
 ccaacaactg gaacaactcc taaagggaaca atcaccaatg aattacttaa aatgtctctg 360
 atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420
 gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480
 gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctgagagttc aattaaaaca 540
 acagaaatag caggtagtgt tctacaacca gatgcacac cttctaaaac tggtagatta 600
 acctcaatag cagttacaat tccagaaaac acctcacagt ctcaagtaat aggcactgag 660
 ggtggaaaaa atgcaagcac ttcagcaacc agccggtctt attccagtat tattttgccg 720
 10 gtggttattg ctttgattgt aataacactt tcagtatttg ttctggtggg tttgtaccga 780
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840
 aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtctgg tgagcactct 900
 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcaataat 960
 tacgcttaat cttcagcttc tatgaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020
 aatcccgact tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgtatg 1080
 15 tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tctgtttctc 1140
 tcacatttaa aaattccatt actccattta caggagcgtt cctaggaaaa ggaatttttag 1200
 gaggagaatt tgtgagcagt gaatctgaca gccacaggag tgggctcgct gataggcatg 1260
 acttctctta atgtttaaag ttttccgggc caagaatttt tatccatgaa gactttccta 1320
 cttttctcgg tgtttctata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380
 gcagggaaaa gttgcacgtg tattattaaa tattaggtag aaatcatacc atgctacttt 1440
 20 gtacatatata gtattttatt cctgctttcg tgttactttt aataaataac tactgtactc 1500
 aataactctaa aaataactata acatgactgt gaaaaatggca aaaaaa

 <210> 31
 <211> 750
 <212> DNA
 25 <213> Human

 <400> 31

 30 cacttgggca cccccatttt ctaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60
 aagggaagtg cctctgatgg ccacaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120
 atagcaaatg gatccttttt ggccctcctt ggagcatgcc ttccctatct tatccttggc 180
 ccactaaag cagaacgtta cggatatttc tgtttttgcc attggtatgc tatctggcca 240
 aacagccttt ccctaattgg aaaatgcagt cctgtttaaa accttgatt tacgactact 300
 tgtacatgct tgctcattac aattttgaca ttttttcat agtgaagacc ccaaacatat 360
 cagtgaacaa tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420
 35 gtggcaagcc aattttgaaa tatctcattt aaaactcaga ccaattcac tgagttatac 480
 ttttaatagc ttctcagca cactatttcc catgcattaa atatgataaa ataactctatc 540
 actgcccatac ggtcttgtaa aaagggaagtc tgaatacaga gccacaaca ctaaaattgt 600
 ttttctagct acaaagtata gcatcatcaa cacagacacg atttggactc cctgacaggt 660
 ggattggaaa acggtgttta aagagaagag aacattttta cataaatgtc attaagaatc 720
 ccaaaggcct tatttgcac caccgtcccg

 40 <210> 32
 <211> 1620
 <212> DNA
 <213> Human

 45 <400> 32

 gcaattcccc cctccacta aacgactccc agtaattatg tttacaaccc attggtatgca 60
 gtgcagccat tcataagaac cttggtgccc cagaaaaatc tgctcctttt ggtaccaaac 120
 ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180
 atctgtgcaa actctgatga tacctgcctt atgtggattc ttttccacac tgctttcatt 240
 50 tttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300
 atgttctggg ttttttctt ctttttagaa ccccgccctc atttaaaaaa ttaaaaaaaa 360
 aaaaaaaact ttttaacattt aaaaaataaa aattaacaaa atttactta ttccaggaca 420
 cgctggcatt tggactcaat gaaaaggcca cctaaagaaa ataaggctga ctgaatgttt 480
 tcacataattt tcacacaata acagtccctt tctatccagc ttgccttcca tttatctcta 540
 gggtagctt ttcaggcaac atccttggtc attgcccaga aagtacctga gctatcagt 600
 attggaatgg cacaggaaac cgaatcacat gggcgccctc cccttggtt tcaagtatct 660
 55 tggagtgtg cacaataatt aggtcatgcc ttgagtgctc tggtctttta acctaccctt 720
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaatgt 780

EP 1 586 333 A2

5 gtgttcctcc taggttgaa gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840
 gtcagttgtg tcttttcacc tcgattttgt aattaataga attgggggga gaggaaatga 900
 tgatgtcaat taagtttcag gttttggcatg atcatcattc tcgatgatat tctcactttg 960
 tcgcaaatct gcccttatcg taagaacaag tttcagaatt ttccctccac tatcagactc 1020
 cagtattatg tttacaatcc attggatgag tgcagcatta taagaccttg gtgccagaa 1080
 aaatctgtcc tttttggtac caaacctgag gtcttttggg agataatgta gaaaaccact 1140
 acctattgaa ggcctgtttt ggctaattctg tgcaaaactct gatgatacct gcttatgttg 1200
 attcttttcc acactgcttt catttttaag tataaagact tagaaaaacta gaataatgct 1260
 tttacaataa attaaaagta tgtgatgttc tgggtttttt ccttcttttt agaaccctgt 1320
 10 atttaaacia gccttctttt taagtcttgt ttgaaattta agtctcagat cttctggata 1380
 ccaaatcaaa aacccaacgc gtaaaacagg gcagtatttg tgttcctaata tttaaaaagc 1440
 tttatgtata ctctataaat atagatgcat aaacaacact tccccttgag tagcacatca 1500
 acatacagca ttgtacatta caatgaaat gtgtaactta agggatttat atatatataa 1560
 acatatatac ctttgaacc tttatactgt aaataaaaaa gttgctttag tcaaaaaaaa 1620

 15 <210> 33
 <211> 2968
 <212> DNA
 <213> Human

 <400> 33

 20 gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60
 gaggaggaag aagaggaaga agaagatgaa gaaagtgaag aggaggagga agaggaggga 120
 gaaagtgaag gcagtgaagg tgatgaggaa gatgaaaagg tgtcagatga gaaggattca 180
 gggaagacat tagataaaaa gccaaagtaa gaaatgagct cagattctga atatgactct 240
 gatgatgac ggactaaaga agaaagggct tatgacaaag caaaacggag gattgagaaa 300
 25 cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360
 gtacttgggc atgtggacac agggaaagca aaaattctag ataagctccg tcacacacat 420
 gtacaagatg gtgaagcagg tggatcaca caacaaattg gggccacca tgttctctct 480
 gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540
 ccaggaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600
 ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg tttggagccc 660
 30 cagacaattg agtctatcaa ccttctcaaa tctaaaaaat gtcccttcat tgttgactc 720
 aataagattg ataggttata tgattgaaa aagagtcctg actctgatgt ggctgctact 780
 ttaaagaagc agaaaaagaa tacaaaagat gaatttgagg agcgagcaaa ggctattatt 840
 gtacattgtc tttgtgacac tttgaaatgt ctttgtttt atgagaataa agatccccgc 900
 acttttgtgt ctttggatcc tacctctgca catactggtg atggcatggg aagtctgac 960
 taccttcttg tagagttaac tcagaccatg ttgagcaaga gacttgacca ctgtgaagag 1020
 35 ctgagagcac aggtgatgga ggttaaagct ctcccgggga tgggcaccac tatagatgtc 1080
 atcttgatca atggcggttt gaaggaagga gatacaatca ttgttctctg agtagaaggc 1140
 cccattgtaa ctgagattcg aggcctcctg ttacctctc ctatgaagga attacgagt 1200
 aagaaccagt atgaaaagca taaagaagta gaagcagctc agggggtaaa gattcttgga 1260
 aaagacctgg agaaaacatt ggctggttta cccctccttg tggcttataa agaagatgaa 1320
 atccctgttc ttaaaagatg attgatccat gagttaaagc agacactaaa tgctatcaaa 1380
 40 ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttctttgga agctctactg 1440
 gaatttctga aaacatcaga agtgccctat gcaggaatta acattggccc agtgcataaa 1500
 aaagatgtta tgaaggcttc agtgatgttg gaacatgacc ctgagtatgc agtaattttg 1560
 gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatatgtt aggagttaga 1620
 attttttagt cagaaattat ttatcattta tttgatgcct ttacaaaata tagacaagac 1680
 tacaagaaac agaaacaaga agaatttaag cacatagcag tatttccctg caagataaaa 1740
 atcctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacgggtgaa 1800
 45 gcaggtcagg tgaacacagg gacacccatg tgtgtcccaa gcaaaaattt tgttgacatc 1860
 ggaatagtaa caagtattga aataaaccat aaacaagtgg atgttgcaaa aaaaggacaa 1920
 gaagtttgtg taaaaataga acctatccct ggtgagtcac ccaaaatggt tggagacat 1980
 tttgaagcta cagatattct tgttagtaag atcagccggc agtccattga tgcactcaaa 2040
 50 gactgttcca gagatgaaat gcagaagagt gactggcagc ttattgtgga gctgaagaaa 2100
 gtatttgaaa tcatctaatt ttttcacatg gagcaggaac tggagtaaat gcaatactgt 2160
 gtttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttg gacactgatg 2220
 gacttaagta tggaggaag aaaaataggt gtataaaatg ttttccatga gaaaccaaga 2280
 aacttacact ggtttgacag tggtcagtta catgtccca cagttccaat gtgctgttc 2340
 actcacctct cccttcccca acccttctct acttggtgc tgttttaaa tttgcccttc 2400
 cccaaatttg gatttttatt acagatctaa agctctttcg attttatact gattaaatca 2460
 55 gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattcttgg gacttttttg 2520
 acgtaagaaa tacttcttta tttatgcata ttcttccac agtgattttt ccagcatttc 2580
 tctgccatat gccttttaggg cttttataaa atagaaaatt aggcattctg atatttcttt 2640

EP 1 586 333 A2

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacgagt ccatgtgtaat catcacaaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 5 ggtatgccag cacctgggta acagtaggag attttatata ttaatctgat ctgtttaatc 2940
 tgatcgggtt agtagagatt ttatacat

<210> 34
 <211> 6011
 <212> DNA
 10 <213> Human
 <400> 34

15 acggggcgcc ggacgaccg cacaatttat cctccacgcc cactcgcac tcggagcggg 60
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120
 cggcttgagc cgagcgagc acccccgcg ccccgcgcca gaagtttggt tgaaccgggc 180
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240
 20 ggaactcccc cggcccaagg ctctgaggct cgggggtcgg cggccgcaga aggggcccgg 300
 tccgcccgcg aggggaggcg ccccggggga cccgagaggg gggtagggac cgcgggctgc 360
 ttgtgcggcg cgggcagcgt gtgcccgcg caggggaggc gccgcccgcg tcccggcccg 420
 gctgcgagga ggaggcgcg gcggcgagga aggatgtact tggtaggggg ggacaggggg 480
 ttggccggct gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcg 540
 tccggcaccc gggcgctggt ctgctgccc tgtgacgagt ccaagtgcga ggagccagg 600
 25 aaccgcccgg ggagcatcgt gcaggcgctc tgccgctgct gctacacgtg cgcagccag 660
 ggaacgaga gctgcggcg cactctcggg atttacggaa cctgcgaccg ggggctgctg 720
 tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcgcttgc 780
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcccttcag ctttaaagag aattgaagaa 960
 30 gagaagccag attgctccaa ggcccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020
 gattctgttc tgatcgaggg ttatgtcctt cctggggagt gctgtccctt acccagccgc 1080
 tgccgctgca accccgagg ctgtctgcgc aaagtctgac agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaacca 1200
 gttttcgggc tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 ccggacagct atgaaactca agtcagacta actgcagatg gttgtgttac tttgccaaca 1320
 35 agatgcgagt gtctctctgg cttatgtggt ttcccctgtg gtgaggtggg atccactccc 1380
 cgcatagtct ctctgtgcga tgggacacct ggaagtgtct gtgatgtctt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccggc 1560
 cagtgtgggt agataaactg cgagaggtaac tacgtgcccc aaggagagtg ctgcccagt 1620
 tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgccaa tggcctgatc 1680
 40 cttgccacag gagaccggtg gcgggaagac gactgcacat tctgccagt cgtcaacgg 1740
 gaacgccact gcgttcgcag cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagtgtatcc acctgcatgt 1860
 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920
 cacaatggtt gtcggacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggt ttccttactg atgcccacaa ctgtgagatc 2040
 45 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 ctctcatgca gtaagatctg ccccttgggt ttcagcagg acagtcacgg ctgtcttatc 2220
 tgcaagtgcga gagaggcctc tgcttcagct gggccaccca tccgtgcggg cactgtgtctc 2280
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgccgtgtgc 2400
 50 aacccacca ttcaccctgg acagtgtgtc ccatcatgtg cagatgactt tgtggtgcag 2460
 aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520
 ggagaaacgt ggaacattga ctccgtgact cagtgcacct gccacagcgg acgggtgtctg 2580
 tgtgagacag aggtgtgccc accgtgtctc tgccagaacc cctcacgcac ccaggattcc 2640
 tgctgcccac agtgtacaga tcaacctttt cggccttctt tgtcccga taacagcgta 2700
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 55 ccggtttgta ccagctgcat ctgcattgat agcgaatta gctgtttctc tgagtcctgc 2820
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc actactgcata 2880
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

EP 1 586 333 A2

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgcagggcca	gacctctgc	3000
	tgcaccgtca	gctgcccccc	tctgccctgt	gttgagccca	tcaacgtgga	aggaagtgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
	aaccatcgag	gagaggttga	cctggagggt	ccctgtggc	ccacgcctag	tgaaaatgat	3180
5	atcgctccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgcctctcta	ttataatagc	attcctattc	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgctggg	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
	gactgcaaga	aaggaaccag	agtccagggtg	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggtctctac	agcatgcaaa	aacagaacca	tctacaggca	3540
10	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgaggtttca	aaagacggaa	3600
	agactgctaaa	tactgctctaa	aaagctaaact	agaattttgtg	cacttgctta	gtggatttga	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
	atgtgcagaa	caagcattcc	cacttttctc	caagataact	gaccaagtgt	tttcttagaa	3780
	ccaaagtgtt	taaagtgtgt	aagatatatt	tgctgttaag	atagctgtag	agatatttgg	3840
	gggtgggaca	gtgagtttgg	atggggaaag	gggtgggagg	gtggtgttgg	gaagaaaaat	3900
15	tggtcagctt	ggctcgggga	gaaacctggt	aacataaaaag	cagttcagtg	gcccagaggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctgggtgtgtg	caaagctcag	gcttgaatga	4020
	gcaggaaaca	aaaaaggcct	tgcgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
	agcacactaa	actcgtctta	cagccatccc	aggtctaaag	ccacaagtgt	cttttctata	4140
	cagtcacaac	tgcaagtaggc	agtgaaggaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	tcttccaagc	4260
20	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatctcttg	4320
	atgtgcagac	gtgagctttg	tttttttaca	agctgacagg	aagaggaggg	agagggttga	4380
	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tggtgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgttttg	ggattctttt	tccttattat	atactgattc	tacaaaatag	aaactacttc	4560
	atttttaattg	tatatatttc	aagcactttt	gttgaagctc	aaaaaaaatg	atgcctcttt	4620
25	aaacttttagc	aattatagga	gtattttatgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
	tttgtgtgca	tgtgtatata	atatatatata	atacatatat	atttatacac	atacaattta	4740
	tgttttcctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattgccatag	cagtgcctttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
30	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
	attcctttat	taaaatcttc	ctcatttgga	tttgctttca	gttggttttc	aatttgctca	5040
	ctggccagag	acattgatgg	cgttccttat	ctgcatcact	aatcagctcc	tggtttttt	5100
	tttttttttt	tcaaacatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttggtg	tagtatgcct	caaataatac	tgactgtata	ctatagtgg	aacttttcaa	5220
	acagccctta	gcacttttat	actaattaac	ccatttgtgc	attgagtttt	cttttaaaaa	5280
35	tgcttgttgt	gaaagacaca	gatacccagt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaactttcaa	gtattgttgt	aaatacttgg	acagagggtg	ctgaacttta	5400
	aaaaaaatta	atttattatt	ataatgacct	aatttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aagggtgtct	agctgtttgc	atcaaaggaa	5520
	aaaaagattt	attatcaagg	ggcaatattt	ttatcttttc	caaaaataaat	ttgttaatga	5580
	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
40	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	tttgtttttt	5700
	caatcatggc	catattatga	aaatactaac	aggatatagg	acaagggtga	aattttttta	5760
	ttattatttt	aaagatatga	tttatcttga	gtgctgtatc	tattactctt	ttactttggt	5820
	tctgttgtgt	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaat	agatatatgg	5880
	cacttgaggt	gcacatagtt	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
45	aaaaaaaaaa	a					
	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
50	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvclpc	deskceepn	rpqsvqgvc	60
	gccytcasgg	nescggtfqi	ygtcdrglrc	virpplngds	lteyeagvce	denwtddqll	120
55	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpgc	240

EP 1 586 333 A2

5 ccdlyeckpv fgvdcrvec ptvqqtacpp dsyetqvrllt adgcctlprr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydqdmfr mdncrfrcrq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsncctlrk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlnpcfgf ltdaqnceic ecrprpkkr 540
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhhknee swndgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfvvg etwnidsctq ctchsgrvlc etevcppllc 720
 qnpsrtqdsq cpqctdqpfr pslnrnnsvp nyckndegdi flaaeswkp d vctscicids 780
 10 viscfscscsp svscerpvlr kgqccpvcik dtipkkvvch fsgkayadee rwdldscstc 840
 yclqggtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekt n hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrh psedssldsi asvvvpiic lsiiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgrtrqv d ssqrmlriae pdarfsgfys 1020
 mqkqnhlqad nfyqtv

15 <210> 35
 <211> 716
 <212> DNA
 <213> Human

20 <400> 35

25 gcagtagctg gagggtcctg cagggggaaa gccaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctgggcccgc tctgcccggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtcagc agggatcagc cccagaacac accctcctcc ccgggacgac gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgaggggat ctcctgattc tctttatagc acctcaaaact gaccatacta aacagtgtag 360
 aagggtcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtgagg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggt ctttaagacc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 30 tctggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

35 <210> 36
 <211> 395
 <212> DNA
 <213> Human

<400> 36

40 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcttttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gccagtaaaa accaaagtca gggttaacaa gtgcatttta caaaatgta aaacccta 300
 tgcagttcct tttttaaatt attttaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

45 <210> 37
 <211> 134
 <212> DNA
 <213> Human

50 <400> 37

ccctcgagcg gccgcccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gacttccat 120
 aaggacacc gtgt

55 <210> 38
 <211> 644
 <212> DNA

EP 1 586 333 A2

<213> Human

<400> 38

```

5   aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
    cagtggcgct tgagttgggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
    gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
    ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga gaaactgag 240
    gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
    ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaaga 360
10  aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
    ttcgcaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480
    caagaggaaat gcatctctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
    tcaaaggctt ctttggaaaa actggaaga aagcagttaa agcagtttct gtgggtctaa 600
    gcagatggac tcagagggtg tggatgaaaa actaaggacc tcac

```

<210> 39

<211> 657

<212> DNA

<213> Human

<400> 39

```

20  ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
    cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggg tcttggccca 120
    gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
    tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
    acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
25  agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
    tggctccttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
    ttttttgttt tttacacgaa tggaaaaatg atgtgttaagt ggtatagatt ttaatcagct 480
    aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
    taagaaatac tactacattt aacattataa agtagagtgc tggacataac tgaaaattag 600
    atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac

```

<210> 40

<211> 1328

<212> DNA

<213> Human

<400> 40

```

35  acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60
    ctggttagtt tttgtaggct cattatggtt agggctggtt agatgtatat aagaacctac 120
    ctatcatgct gtatgtatca ctccattccat ttcatgttc catgcatact cgggcatcat 180
    gctaatatgt atccttttta gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
    ggtaaaaaaa attccccaaa tattttgcac tgaatgtacc aaagggtgaag ggacattaca 300
    atatgactaa cagcaactcc atcacttgag aagtataata gaaaaatagct tctaaatcaa 360
    acttccttca cagtgcctgt tctaccacta caaggactgt gcatctaagt aataattttt 420
    taagattcac tataatgtgat agtatgatat gcatttattt aaaaatgcatt agactctctt 480
    ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat tccccccact 540
    gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
45  tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
    actcagaact atatttctaa gcctgcattt tccactgatgc ataattttct tagtaattat 720
    aagagacagt ttttctatgg catctccaaa actgcagtac atcactagtc ttacttctgc 780
    ttaattttat gagaaggat tcttcatatt aattgctttt gggattactc cacatctttg 840
    tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaaagc 900
    attggattga catatggttt gccagcctat ggggtttacag gcattgcccc aacatttctt 960
50  tgagatctat atttataagc agccatggaa ttctatttat gggatgtttg caatcttaca 1020
    ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
    gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
    ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggg tatagaaatc 1200
    tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
55  ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
    tgaaaaaa

```

EP 1 586 333 A2

<210> 41
<211> 987
<212> DNA
<213> Human

5

<400> 41

10 aacacagagact ggcacaggac ctcttcattg caggaagatg gtagttagg caggtaacat 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatgggtg 120
taacccccgg ctatcagtcc ggatggttgc caccctcct gctgtaggat ggaagcagcc 180
atggagtgagg agggaggcgc aataagacac ccctccacag agcttgcat catgggaagc 240
tggttctacc tcttctggc tcttttgtt aaaggcctg ctgggagcct tccttttggg 300
tgtctttctc tcttccaacc aacagaaaag actgctcttc aaaggtggag ggtcttcag 360
aaacacagct gccaggagcc caggcacagg gctgggggcc tggaaaaagg agggcacaca 420
ggaggaggga ggagctggta gggagatgct ggctttacct aaggtctcga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540
15 tgcattagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
tgaggctgtg gatacctgtt ttgaagggtt gctgagaaaa ttaagataa gggatccaa 780
aatagctcac ggcataacca ccctgaacgt gcctaattctc gtaagctaag cagggtcagg 840
20 cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttgg 900
actctgtctt aacagttagc tggcacacag aaggcactca gtaataactt gttgaataaa 960
tgaagttagc atttggtgtg aaaaaaa

<210> 42
<211> 956
<212> DNA
<213> Human

25

<400> 42

30 cggacggtgg ggcggacgcg tgggtgcagg agcaggcgcg ctgccgactg ccccaaccaa 60
ggaaggagcc cctgagtcgg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
ttgcctgtct aaagccttaa ctaagactcc cgccccggc tggccctgtg cagaccttac 180
tcaggggatg tttacctggt gctcgggaag ggaggggagg gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcgccc agggcgcca gggaccaaa gcaggatgac 300
cacgcacctc cacgccactg cctcccccca atgcatttgg aaccaaagtc taaactgagc 360
tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agcgtctctg acagatggac 420
gcaggccctg tccagcccc agtgcgctcg ttccgggtccc cacagactgc cccagccaac 480
35 gagattgtcg gaaaccaagt caggccagggt gggcgacaa aagggccagg tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt ttttttcaca catcgttgcc gcagcggtgg 600
gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660
tgaattaatt cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720
tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcgggtg accccatcac 780
40 tcgcaggacc aagggggcg ggactgctgg ctacgcccc gctgtgtcct ccctccctc 840
ccttccttgg gcagaatgaa ttcatgctg attctgtggc cgccatctgc gcagggtgg 900
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

<210> 43
<211> 536
<212> DNA
<213> Human

45

<400> 43

50 aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaataaaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300
cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420
55 ctggaaaaag tgggttatgc cacttttaaa accctttctg gtaaatatta tggtagctaa 480
agggtgggtt ccccgccacc tggacctgga caggtagggt tccgtgggtt accagt

EP 1 586 333 A2

<210> 44
<211> 1630
<212> DNA
<213> Human

5

<400> 44

10 ggggaggggac gagtatggaa cctgaaggt agcaagtcca ggcaactggcc tgaccatccg 60
 gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
 tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
 atccccctctg gagggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
 ccatccaggt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
 gtgatattccc ttaggcccag gacttgggcc tccagctcat ctgttccttc tgggcccatt 360
 catggcaggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
 gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
 15 tacttgttac gggaaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
 gacagatttg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
 attaggaagt cgggggtggg tgggtgggtt gggctagtgt gggttgaatt taggggccga 660
 tgagcttggg tacgtgagca ggggtgttaag ttagggtctg cctgtatttc tgggtcccctt 720
 ggaaatgtcc ccttcttcag tgctcagacct cagtcccagt gtccatatcg tgcccagaaa 780
 agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcttggg 840
 20 gccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900
 tgtgattcag gtcccagggt gggactcagg gaggaatatg gctgagtctt gtagtttcca 960
 gagttggctg gtagagcctt ctagagggtc agaatttag cttcaggatc agctgggggt 1020
 atggaattgg ctgagatga aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
 tgagggacag tttgggtttg ggacttacca gggatgatgt agatctggaa cccccaagt 1140
 aggctggaag gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttgggaatg 1200
 25 aaagagtgac cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260
 gaagggtgctc ttactcagtt aatgatgagt gactatatct accaaagccc ctacctgctg 1320
 ctgggtccct tgtagcacag gagactgggg ctaagggcc ctcccaggga agggacacca 1380
 tcaggcctct ggctgaggca gtacataga ggatccattt ctacctgcat ttcccagggt 1440
 actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgccctg gctgttctct 1500
 cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
 30 cctcttgctt cttgtagaat gcagctctgg ccctcaataa atgcttcctg cattcatctg 1620
 caaaaaaaaa

<210> 45
<211> 169
<212> DNA
<213> Human

35

<400> 45

40 tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
 taaaactggg ttatgatctt cagtctgatt ccagtgtctg ataactagat aacgtatgaa 120
 ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagtgtga

<210> 46
<211> 769
<212> DNA
<213> Human

45

<400> 46

50 tgcaggtcat atttactatc ggcaataaaa ggaagcaaa cagtattaa cagcgggtga 60
 atttgtcgct ttacttttt ataaagtgtc acataaaatg tcatatttcc aaatttaaaa 120
 acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180
 aaacaaaaac aaaaaacaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240
 aagggtgtact aggcaatctt agagatctgg caacttatct tatatataag gcatctgtga 300
 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
 cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
 ggccagctcc ttctctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
 catgccagtg aatgagaaaa caagcatgga atatatataac tttaacatta aaaaatgttt 540
 55 tattttgtaa taaaatcaaa ttcccattg aaaccttcaa aaactttgca gaatgaggtt 600
 ttgatataag tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
 cctgcctttt tgtttttaaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

EP 1 586 333 A2

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
<211> 2529
<212> DNA
<213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
gtgaaaatta gtgactgggt aagggtgtgcc actgtacata tcatcatttt ctgactgggg 120
tcaggacctg gtccctagtc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
gccttactta gctcctggca gagggtagt ggggacctac gaggttcaaa atcaaatggc 360
atttgccag cctggcttta ctaacaggt cccagagtgc ctctgttggc tgagctctcc 420
15 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctacct acaacttttc 480
attattcttc tggaaaccca tttctgttga gtccatctga cttaagtct ctctccctcc 540
actagtggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
ccagagggcc gcgcaacttt gcggatttcc agaagggtat aaaaagagca ctcttgagt 660
gggtgccagg aatgttttaa atctatcagg cacactataa agctggtggt ttcttctac 720
caagtggatt cggcatatga accacctact caatacttta tttttgtct gtttaaacac 780
20 tgaactctgg tgttgacagg tacaaaggag aagagatggg gactgtgaag aggggagggc 840
ttccctcatc ttctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
gcaatagatg gggcttccca ccatttgttg gttattgctg ggggttagcca ggagcagtgt 960
ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttggggtct 1020
ccagaaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
agggtgaacag tcctacctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
25 ttatgaaact gaaaatcaaa tcaaggtatt ggaagaata atttccctc gattccacag 1200
gaggggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260
acaaatcatc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320
caaggagttt tcagggaact ctatcaagcc atacaaaat cagggtcaca tgtgggtttc 1380
ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgc 1440
gcagtggggc tgacctgaca aagccccagc tttcctgttg caggttctgg gagaggatgc 1500
30 attcaagctt ctgcagccta ggggacaggc ctgcttgttc agttattact gcctcggagc 1560
tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
cttcggcagt attctcggt gtatgttctc tggcagagag aggcagatga acatagtttt 1680
agggagaaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
35 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
gggggagtgagg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
ctctatctga ggagccccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
tgaaaatttc cagaaatacc atttgggtgca tccctttgtt tctgtaatat taaactcagg 2100
tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220
40 gcctgaagtt atagagtgtt tacagcggtg gcgatattca ggggtcatcg ccaactggtc 2280
tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtacca 2400
gtccagagcc ctgccacgga tgtacgcagg agccagcat taggcaatca ggagccagaa 2460
catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
45 ggggtgtcc

<210> 48
<211> 1553
<212> DNA
<213> Human

<400> 48

55 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
ttcatatata tatatacata catatatataa ggaaacaatt tgcaaattta cacacctgac 120
aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
ctagccaggc ccgtttttcca tccctaagta ccattctctc atttggggcc ttctaggggt 240
ggggccctga gcttgggttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

EP 1 586 333 A2

5 ccatcaagag ggctatggga gccaaagtga cacgggggat tgaggctaatt tcacctgaac 420
 tcgaaaaacag cgcccagcct cctcaccgca ggacgcgctc ttttcttttt ttttcctcga 480
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgccgcct cgccctccca 720
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgcat cttttaagga 780
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 agacaggagg gtgggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900
 cgagagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 10 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020
 aggtaccoca gctcagctgc tggcaggagc caggatttta cagccataat gtgtgtaaac 1080
 aaaaaacacg tcttgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatgggt gtggactggt ccctgaaaag cgggccttgc 1200
 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgagggggag gaggaggctt tctctaagtc ctttgagggc tttggctgag agaagagtga 1320
 15 gcaggggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaattgcc 1380
 tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgccct 1440
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgtctc 1500
 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

 <210> 49
 <211> 921
 <212> DNA
 <213> Human

 <400> 49

 25 ctgtgggtccc agctactcag gaggctgagg cgggaggatt gcttgagccc aggagttgga 60
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gcctgtcaga acacttggtt actcctaccc cagatcagtg gacctgggaa tgagggttg 240
 tccccggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300
 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 30 ggagggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420
 tgcgtgcctg tgtgtgtgag tgcccctccc ctgcagcgt cgggtggtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagact 540
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
 cagggtgctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
 gtcccgtgga cctgcccccg tggcgtctca cggtgatgcc tgctcctgac attgggtgtc 720
 35 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840
 tactttgacc tcttgccctac aacccttcc ttgggtccga ggctggtagc tttgttact 900
 tcagatgggt gggggcgggt g

 <210> 50
 <211> 338
 <212> DNA
 <213> Human

 <400> 50

 45 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac ttccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttctg 240
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgc atttgctaca 300
 50 gtaagaaact ttctttcttg aattcttggt tctcttgg

 <210> 51
 <211> 1191
 <212> DNA
 <213> Human

 55 <400> 51

EP 1 586 333 A2

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	ccgggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tgttggctct	ctgtgccact	120
	cctggaaaaa	aatgaattgg	gtaaggaa	gttaataaga	aaatgtgcct	tgctaactgt	180
	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
5	aaacttgctca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgctcgga	gacgctcctg	acaagtcggg	360
	aatttctcta	tttctccact	gggtgcaaaga	gcggatttct	ccctgcttct	cttctgtcac	420
	ccccgctcct	ctccccaggg	aggctccttg	atttatggta	gctttggact	tgcttccccg	480
	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	gggtgaaggga	agactccagg	540
	ccatcacaga	taaaagaaaa	atacagggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
10	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gagggagaaa	tggcttctag	660
	atggaatcag	ctcgggaaaa	gaacagggaag	agatgaagaa	gcaaaatcaa	caagaccagg	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
	aaaaagctga	actgcaaatc	tcaacgaagg	aagaggccat	tttaagaaa	ctaaagtcaa	840
	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaaagaaa	gaaagagcag	900
	aagagtcagt	tgaggacatc	tatgtctaata	tccttgacct	tccaaagtcc	tacatacctt	960
15	ctagggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaaattaaa	gttgaaaaag	actgaagac	tggagaaagt	acagttctgt	1080
	cttccaatac	ctctggccat	cagatgactt	taaaagggtac	aggagtaaaa	gtttaagatg	1140
	atggggcaaaa	gtccagtgtg	ttcagtaaa	tgctaatac	aagttggagg	t	
	<210>	52					
20	<211>	1200					
	<212>	DNA					
	<213>	Human					
	<400>	52					
25	aacagggact	ctcactctat	caaccccagg	ctggagtccg	gtgcgcccac	cctggctccc	60
	tgcaacctcc	gctcccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcct	ttttttaga	gacaggggtt	180
	cgcttctgt	ccaggccggc	atcatatact	ttaaatcatg	cccagatgac	tttaatacct	240
	aatacaatat	atcaggttgg	tttaaaaaata	attgcttttt	tattattttt	gcatttttgc	300
	accaacctta	atgctatgta	aatagttgtt	atactgttgc	ttaacaacag	tatgacaatt	360
30	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtg	tttcaattcc	tccttgggtg	aatccatgga	tgcaaaaccc	acagatatga	480
	agggtctggc	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagt	aaagtattgg	tacagtggaa	agagttagtg	aaaacataaa	catttggacc	600
	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggctc	660
	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagctc	cagttgcctc	720
35	acctgtaaaa	tgaagaact	ggatactctc	taagggtcact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaat	840
	gattattaaa	gtgggaaaaa	gccaatgtct	tctcttagaa	agctcaacta	aatttgagaa	900
	gaataatctt	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctatttattt	960
	agagatgggg	tctcactctg	tcacccagac	tggagtacag	tggcacaatc	atagctcaat	1020
40	gctgcctcaa	attcatgggc	tcaagtgate	ctcctgcctc	tgccctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgtatt	gacctattta	tttattgtga	1140
	tttatactct	tttttttttt	tctttttttt	tttttttaca	aatcagaaat	acttattttt	1200
	<210>	53					
	<211>	989					
	<212>	DNA					
45	<213>	Human					
	<400>	53					
50	aagccaccac	tcaaaacttc	ctatacattt	tcacagcaga	gacaagtga	cattttatttt	60
	tatgcctttc	ttcctatgtg	tatttcaagt	cttttttcaa	acaaggcccc	aggactctcc	120
	gattcaatta	gtccttgggc	tggtcgactg	tcaggaagtc	cagggagcct	ctacaaatgc	180
	agagtgactc	tttaccacaa	taaaccttag	atacatgcaa	aaagcaggac	ccttccctca	240
	ggaatgtgcc	atttcagatg	cacagcacc	atgcagaaaa	gctggaattt	tccttggaa	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccaggct	gagtgcattg	cgtgatctca	ctcactgcaa	ttccacctcc	420
	agggtcagg	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccaccatg	480
55	ccggctaatt	ttgtattttt	gtagagatgg	atttctccat	ttgggtcagg	gggtctcgaa	540
	cccaacctca	gtgatctgcc	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

EP 1 586 333 A2

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660
 ttctctgaag tacttgataa aattttccaaa caaacacat gtccacttca ctgataaaaa 720
 atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
 ttaagatttc ttacgaaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840
 5 ttaatatatt tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900
 tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtg c actggcgcaa 960
 gcccggctca ccgcaatctc tgccaccgc

<210> 54
 <211> 250
 10 <212> DNA
 <213> Human

<400> 54

catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60
 gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120
 agtggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
 aaagggcatt cttaggaac tgcattctgt aacccacacc ttgatccaag agctaggga 240
 acttcagttg

<210> 55
 <211> 2270
 20 <212> DNA
 <213> Human

<400> 55

gcgccccga gcagcgccc cgccctccgc gccttctccg ccgggacctc gagcgaaaaga 60
 ggccccgcgc ccgcccagcc ctgcctccc tgccaccgcg gcacaccgcg ccgccacccc 120
 gaccccgctg cgacggccct gtccgctgca caccagcttg ttggcgctct ctgcgcccgc 180
 ctgcgcccgc gctactcctg cgcgccacaa tgagctcccg catcgccagg gcgctcgcc 240
 tagtcgtcac ccttctccac ttgaccagge tggcgctctc cacctgcccc gctgcctgcc 300
 actgccccct ggaggcgccc aagtgcgcgc cgggagtcgc gctggtccgg gacggctgcg 360
 30 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420
 accacaccaa ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480
 gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaacgggg 540
 aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600
 ttctctgtg tccccaagaa ctatctctcc ccaacttggg ctgtcccaac cctcggtcg 660
 tcaaagttac cgggcagtg tgcgaggagt gggctctgta cgaggatagt atcaaggacc 720
 35 ccattgagga caaccgagc ctcttggca aggagctggg attcgatgcc tccgagtggt 780
 agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggctcc 840
 ctgttttttg aatggagcct cgcattctat acaacccttt acaaggccag aaatgtattg 900
 ttcaaaacac ttcatggtcc cagtgtcaa agacctgtg aactggatc tccacacgag 960
 ttaccaatga caacctgag tgccgccttg tgaaagaaac ccgattttgt gaggtgcggc 1020
 40 cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080
 aatccccga accagtcagg tttacttacg ctggatgttt gagtgtgaag aaataccggc 1140
 ccaagtactg cggttctctg gtggacggcc gatgctgcac gccccagctg accaggactg 1200
 tgaagatgcg gttccgctgc gaagatgggg agacatttct caagaacgctc atgatgatcc 1260
 agtctgcaa atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320
 ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380
 45 cctagacaaa caagggagaa gagtgtcaga atcagaatca tggagaaaat gggcggggg 1440
 ggtgtgggtg atgggactca ttgtagaaaag gaagccttgc tcattcttga ggagcattaa 1500
 ggtatttcga aactgccaa ggtgctgggt cggtatgaca ctaatgcagc cagatttga 1560
 gaatactttg ctcatagta ttggagcaca tgttactgct tcatttttga gcttgtggag 1620
 ttgatgactt tctgttttct gtttgtaaat tatattgtaa gcatatttct tctaggcttt 1680
 tttccatttt gggttctaca gtcgtaaaag agataataag attagtttga cagtttaaa 1740
 50 cttttattcg tcttttgaca aaagtaaatg ggagggcatt ccatcccttc ctgaaggggg 1800
 aactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
 ggtgttttaa gactgaatgt tttatttatt aaaatgtagc ttttggggag ggaggggaaa 1920
 tgtaatactg gaataatttg taaatgattt taattttata ttcaagtgaag agattttatt 1980
 tatggaatta accatttaaa aaagaaatat ttacctaata tctgagtgtg tgccattcgg 2040
 tattttttaga ggtgctccaa agtcattagg aacaacctag ctacagctact caattattca 2100
 aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160
 55 ttataccttc agtagagaaa agtcttttga tataaagtaa tgtttaaaaa acatgtattg 2220
 aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

EP 1 586 333 A2

<210> 56
 <211> 1636
 <212> DNA
 <213> Human
 5
 <400> 56
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagga 60
 agcgctcgag ttggaagga accgctgctg ctggccgaac tcaagcccg ggcgccccac 120
 cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctccc agatggctcc 180
 tggtttgctt ggtctcaagg acactgcatc gtcaaactga tcccctggcc gttggaggag 240
 cagttcatcc ctaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaagg 300
 cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctggg gctggccttc 360
 agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtgcc 420
 gatgtctctt gcttggttct tgctacggga ctcaacgat ggcagatcaa gatctgggag 480
 gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
 agcttcacac ccagtggcag tttgattttg gtctccgct caccggataa gactcttcgc 600
 atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660
 gtttactctt gttccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720
 tcggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
 agcagtgttg tctctgtga cttctcccc gactctgccc tgcctgtcac ggcttcttac 840
 gataccaatg tgattatgtg ggacccctac accggcgaaa ggctgaggtc actccaccac 900
 acccaggttg acccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
 tgggcccttg aactgaaac tccattgca tttgctcta tgaccaatgg gctttgctgc 1080
 acattttttc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
 tggacagctc ctagggtcct gtectcactg aagcacttat gccggaaagc ccttcgaagt 1200
 ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagtctctc 1260
 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320
 cctgtcaaag ggagtgtgct gaataatggg ccaaacatct ggtcttgcat tgaatatgca 1380
 tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
 tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagtgtga acttatattg 1500
 aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
 aagatgtgga aggtgaggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
 gacctgtgct tgcgtt
 <210> 57
 <211> 460
 <212> DNA
 <213> Human
 <400> 57
 40
 45
 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
 gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
 tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttgta tgacagcagg 180
 ggcaggagcc cagcaaggga gcctccattc ccaggactct ggagggagct gagaccatcc 240
 atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
 aactgaggct gggaaagtcac atagcaagtg actggcagag ctgggactgg aacccaacca 360
 gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
 ccgagctcga attcgtaatc atggtcatag ctgtttcctg
 <210> 58
 <211> 1049
 <212> DNA
 <213> Human
 <400> 58
 55
 atctgatcaa gaatacctgc cctggtcact ctgcgatgt ttctgtccac ttgttcacat 60
 tgaggacca gataccttt tttacagagg cacttgctcg gtctaacaca gacacctcca 120
 tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccctccca gcctggacta 180
 cagcagcact ttcccggtgg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
 gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
 ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360

5 aaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggacttttgc ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtatata aatccacca ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 ggcagttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 10 aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccgct gagggccaaa gagcagttgc cctccagat gctttctgtg gaggttctgca 1020
 acttcaagaa agactctggc tgttctcaa

 <210> 59
 <211> 747
 15 <212> DNA
 <213> Human

 <400> 59


 20 tttttcaaatt cacatatggc ttctttgacc ccatcaaata actttattca cacaaaacgtc 60
 ccttaatttta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcataataa 180
 gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctcgtctgtc ccacacaaat gttaagaag tcaactgcaat gtactccccg gctctgatga 360
 25 aaagaagccc ctggcacaaa agattccagt gccctgaag aggcctccct cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
 30 gcccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcaattta gtagtaatag cggccgc

35

Claims

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiotensin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiotensin/Tie receptor systems.
3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiotensin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiotensin/Tie receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiotensin/Tie receptor systems.

6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.
- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutic application.
- 15 10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
 - a) compounds which inhibit receptor tyrosine kinase activity,
 - b) compounds which inhibit ligand binding to receptors,
 - 20 c) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 - e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 - 25 f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
- 30 11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of
 - g) compounds which inhibit receptor tyrosine kinase activity,
 - h) compounds which inhibit ligand binding to receptors,
 - i) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 - 35 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 - 40 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.
- 45 13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a
14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.
- 50 15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I




in which

r
 n
 R_3 und R_4

has the meaning of 0 to 2,

has the meaning of 0 to 2;


- a) each independently from each other have the meaning of lower alkyl,
 b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and

m has the meaning of 0 to 4; or

- c) together form a bridge of partial formula III



wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G has the meaning of C_1 - C_6 - alkyl, C_2 - C_6 - alkylene or C_2 - C_6 - alkenylene; or C_2 - C_6 - alkylene

or C₃-C₆-alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-NH-CH₂-, oxa (-O-), thia (-S-) or imino (-NH-), independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,

5 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

 R₁ and R₂ independently from each other have the meaning of H or lower alkyl,


 X has the meaning of imino, oxa or thia;

 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

10 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or

15 an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof,

20 and/or a compound of genaral formula IV




in which



40 A has the meaning of group =NR²,

 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,


 Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-(CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the group



55 or A, Z and R¹ together form the group




m, n and o has the meaning of 0 - 3,
q has the meaning of 1 - 6,
 $R_a, R_b, R_c, R_d, R_e, R_f$ independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,
X has the meaning of group $=NR^9$ or $=N-$,
Y has the meaning of group $-(CH_2)_p$,
p has the meaning of integer 1-4,
 R^1 has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
 R^2 has the meaning of hydrogen or C_{1-6} -alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,
 R^3 has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of fur halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl or C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group





R^8, R^9 and R^{10} independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts,

and/ or a compound of general formula V




in which


20 R^1 has the meaning of group



in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,




in which R^8 is $-CH_3$, fluoro, chloro or $-CF_3$

in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N=C$, $-CH_3$, $-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

R^2 has the meaning of pyridyl or the group



and

R^3 has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/or II (4-Chlorophenyl) [4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage

EP 1 586 333 A2

of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

5

10

15

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6